Breaking News: CHRS – Market Insights, Analysis & Latest Updates

CHRS

Coherus price target raised at Baird on agreement to sell Udenyca

Baird increased Coherus Biosciences' price target to $6 after its $483M Udenyca sale, enhancing financial stability and focusing on its immuno-oncology pipeline.

investing.com • 05/12/2024 - 13:53 PM

CHRS

Coherus shares surge on $558M Udenyca divestiture deal

Coherus BioSciences' shares rose 40% after a $558.4 million asset sale of UDENYCA to Intas Pharmaceuticals, to refocus on immuno-oncology programs and enhance capital structure.

investing.com • 03/12/2024 - 15:25 PM

CHRS

Coherus BioSciences inks $558.4M deal with Intas Pharmaceuticals; shares rally

Coherus BioSciences shares rose after announcing a $558.4 million deal to sell Udencya franchise, with plans to clear financial obligations and update projections in early 2025.

investing.com • 03/12/2024 - 12:24 PM

Greed and Fear Index

Note: The data is for reference only.

Greed

Coherus price target raised at Baird on agreement to sell Udenyca

Coherus shares surge on $558M Udenyca divestiture deal

Coherus BioSciences inks $558.4M deal with Intas Pharmaceuticals; shares rally

Currency